Composition for preventing or treating benign tumor

Patent metadata

Field	Value
Publication number	US-12440546-B2
Application number	US-201917282172-A
Country	US
Kind code	B2
Filing date	Oct 4, 2019
Priority date	Oct 5, 2018
Publication date	Oct 14, 2025
Grant date	Oct 14, 2025

Abstract

The present disclosure provides a composition for preventing or treating a benign tumor. Provided is a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a specific embodiment, the present disclosure provides a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a preferred embodiment, the composition for preventing or treating a benign tumor (e.g. familial adenomatous polyposis) according to the present disclosure comprises a killer type WT1 peptide and/or a helper type WT1 peptide. In a further preferred embodiment, the WT1 peptide is WT1 126 killer peptide and/or WT1 35 helper peptide. In another aspect, provided are a method of inducing WT1 peptide-specific CTLs, a method of inducing WT1-specific helper T cells, and a method of inducing dendritic cells presenting a WT1 peptide.

First claim

The invention claimed is:

1. A method for treating a benign tumor expressing WT1 selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma in a subject, the method comprising:
administering to the subject an effective amount of a peptide selected from the group consisting of
RMFPNAPYL of SEQ ID NO: 2,
RYFPNAPYL of SEQ ID NO: 46,
YMFPNAPYL of SEQ ID NO: 14,
CYTWNOMNL of SEQ ID NO: 45,
CMTWNQMNL of SEQ ID NO: 3,
C-CYTWNQMNL of SEQ ID NO: 47 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond, and
C-CMTWNQMNL of SEQ ID NO: 48 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond.

2. The method according to claim 1 , wherein the method comprises administering a peptide selected from the group consisting of

RMFPNAPYL of SEQ ID NO: 2,

RYFPNAPYL of SEQ ID NO: 46,

YMFPNAPYL of SEQ ID NO: 14,

CYTWNQMNL of SEQ ID NO: 45, 

and

CMTWNQMNL of SEQ ID NO: 3.

3. A method for treating a benign tumor expressing WT1 selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma in a subject, the method comprising:
administering to the subject an effective amount of a conjugate of formula (2) or a conjugate of formula (3),

wherein C-C shown in the formulas (2) and (3) means that the C residues are linked together by a disulfide bond.

4. The method 3 , wherein the method comprises
administering the conjugate of formula (3),

5. The method according to claim 1 , further comprising:
administering at least one peptide selected from the group consisting of

WAPVLDFAPPGASAYGSL of SEQ ID NO: 4,

CWAPVLDFAPPGASAYGSL of SEQ ID NO: 50

and

WAPVLDFAPPGASAYGSLC of SEQ ID NO: 51.

6. The method according to claim 3 , wherein the method comprises administering the conjugate of formula (2), and
a peptide WAPVLDFAPPGASAYGSL of SEQ ID NO: 4.

7. The method according to claim 4 , wherein the method comprises administering the conjugate of formula (3), and
a peptide WAPVLDFAPPGASAYGSL of SEQ ID NO: 4.

8. The method according claim 1 , wherein the method further comprises administering an adjuvant.

9. The method according to claim 8 , wherein the adjuvant is Montanide® ISA51 adjuvant.

10. The method according to claim 1 , wherein the benign tumor is selected from the group consisting of familial adenomatous polyposis, and non-hereditary colorectal adenoma.

11. The method according to claim 10 , wherein the benign tumor is familial adenomatous polyposis.

12. The method according to claim 1 , wherein the administering is once a week.

13. A method for treating a benign tumor expressing WT1 selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma in a subject, the method comprising:
administering to the subject an effective amount of a nucleic acid molecule encoding a peptide selected from the group consisting of
RMFPNAPYL of SEQ ID NO: 2,
RYFPNAPYL of SEQ ID NO: 46,
YMFPNAPYL of SEQ ID NO: 14,
CYTWNQMNL of SEQ ID NO: 45,
CMTWNQMNL of SEQ ID NO: 3,
C-CYTWNQMNL of SEQ ID NO: 47 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond, and
C-CMTWNQMNL of SEQ ID NO: 48 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond.

14. The method according to claim 13 , wherein the nucleic acid molecule includes RNA and/or DNA.

15. The method according to claim 13 , wherein the benign tumor is selected from the group consisting of familial adenomatous polyposis, and non-hereditary colorectal adenoma.

16. The method according to claim 15 , wherein the benign tumor is familial adenomatous polyposis.

17. The method according to claim 13 , wherein the method comprises administering the nucleic acid molecule once a week.

18. A method, comprising:
culturing peripheral blood mononuclear cells from a subject in need of treatment for a benign tumor selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma in the presence of a peptide; and
inducing WT1-specific CTLs and/or WT1-specific helper T cells from the peripheral blood mononuclear cells,
wherein the peptide is selected from the group consisting of
RMFPNAPYL of SEQ ID NO: 2,
RYFPNAPYL of SEQ ID NO: 46,
YMFPNAPYL of SEQ ID NO: 14,
CYTWNOMNL of SEQ ID NO: 45,
CMTWNQMNL of SEQ ID NO: 3,
C-CYTWNQMNL of SEQ ID NO: 47 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond, and
C-CMTWNQMNL of SEQ ID NO: 48 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond.

19. The method according to claim 18 , further comprising administering to the subject an effective amount of the WT1-specific CTLs and/or WT1-specific helper T cells.

20. A method, comprising:
culturing immature dendritic cells from a subject in need of treatment for a benign tumor selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma

Assignees

• Int Inst Cancer Immunology Inc

Inventors

• Sugiyama Haruo

Classifications

• A61K39/001153 Primary

  Wilms tumor 1 [WT1] · CPC title

• C12N2501/415

  Wnt; Frizzeled · CPC title

• C12N5/0639

  Dendritic cells, e.g. Langherhans cells in the epidermis · CPC title

• A61K2039/55566

  Emulsions, e.g. Freund's adjuvant, MF59 · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title